News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Researchers Uncover How MN1 Overexpression Causes AML

Original Publication Date
Article Source
External Web Content
Meningioma-1 (MN1) is a protein whose overexpression has been linked to acute myeloid leukemia (AML) and brain tumors, and 70% to 80% of AML patients with high overexpression of MN1 die within two years. Yet the mechanism by which MN1 causes these diseases has largely remained a…

“If it’s the time, it’s the time”: Existential communication in naturally-occurring palliative care conversations with individuals with advanced cancer, their families, and clinicians

Original Publication Date
Article Source
External Web Content
Highlights We analyzed naturally-occurring inpatient palliative care conversations. Existential communication is pervasive and varied in palliative care conversations Patients, families, and clinicians talk about time, the self, and connectedness. Findings help develop a lexicon…

Integration of Cellular Therapy Jumpstarts Research Efforts in Acute Leukemias

Original Publication Date
Article Source
External Web Content
With the goal of capitalizing on the efficacy observed with cellular therapies in acute leukemias, ongoing research efforts are underway to address unanswered questions regarding the role of transplant in conjunction with cellular therapy, optimal toxicity management, antigen…

Long‐term Results of Low‐intensity Chemotherapy with Clofarabine or Cladribine Combined with Low‐Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
Abstract Background The treatment of older patients with newly diagnosed acute myeloid leukemia (AML) using intensive chemotherapy is associated with treatment intolerance and poor survival. We evaluated two new lower‐intensity regimens with clofarabine (n=119) or cladribine (n…

RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML

Original Publication Date
Article Source
External Web Content
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American…

Post-Traumatic Stress Disorder Prevalent in Patients with Acute Myeloid Leukemia

Original Publication Date
Article Source
External Web Content
Patients with acute myeloid leukemia can experience post-traumatic stress disorder (PTSD) one month after receiving intensive chemotherapy and may benefit from supportive approach-oriented coping interventions, according to data published in Cancer. Previously, there have been…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families